Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Enterprise Value: 2020-2025

Historic Enterprise Value for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to $2.1 billion.

  • Tarsus Pharmaceuticals' Enterprise Value rose 125.53% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 1112.01%. This contributed to the annual value of $1.8 billion for FY2024, which is 312.09% up from last year.
  • Tarsus Pharmaceuticals' Enterprise Value amounted to $2.1 billion in Q3 2025, which was up 59.51% from $1.3 billion recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Enterprise Value's 5-year high stood at $2.1 billion during Q3 2025, with a 5-year trough of $57.2 million in Q2 2022.
  • Its 3-year average for Enterprise Value is $965.1 million, with a median of $934.2 million in 2024.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 1,002.82% in 2021, then plummeted by 86.31% in 2022.
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' Enterprise Value stood at $293.4 million in 2021, then crashed by 40.70% to $174.0 million in 2022, then skyrocketed by 154.57% to $442.9 million in 2023, then soared by 312.09% to $1.8 billion in 2024, then skyrocketed by 125.53% to $2.1 billion in 2025.
  • Its Enterprise Value was $2.1 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.6 billion in Q1 2025.